NCT05734950 (BOLD-70) is a clinical trial of Translational study in Breast Cancer Female, sponsored by Royal Marsden NHS Foundation Trust.

Who is sponsoring NCT05734950?

NCT05734950 is sponsored by Royal Marsden NHS Foundation Trust.

What drugs are being tested in NCT05734950?

Interventions in NCT05734950: Translational study.

What condition does NCT05734950 study?

NCT05734950 studies Breast Cancer Female.

Is NCT05734950 still recruiting?

NCT05734950 is currently status unknown. Last updated 21 February 2023.

Last reviewed 2023-02-21 · How we verify

NCT05734950: BOLD-70

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Biological Characteristics of Older Women (> 70 Years) With ER Positive, HER2 Negative Early Breast Cancer

Status unknown Last updated 21 February 2023

What this trial tests

trial testing Translational study in Breast Cancer Female in 100 participants. Status unknown.

Timeline

21 July 2022

Primary endpoint
31 August 2023

31 August 2023

Quick facts

Lead sponsor	Royal Marsden NHS Foundation Trust
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	100
Start date	21 July 2022
Primary completion	31 August 2023
Estimated completion	31 August 2023
Sites	1 location across United Kingdom

Drugs / interventions tested

Translational study

Conditions studied

Breast Cancer Female — all drugs for Breast Cancer Female →

Sponsor

Royal Marsden NHS Foundation Trust

Who can join

71 and older, female only, with Breast Cancer Female. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is investigating the biological characteristics of early oestrogen receptor (ER) positive, human epidermal growth factor receptor 2 (HER2) negative breast cancer (BC) in older woman (aged \> 70 years) who were treated with adjuvant endocrine treatment (ET). It will use surgical tissue previously collected as part of routine care from patients aged 70 years or older at diagnosis with ER positive, HER2 negative stage I-III BC treated The Royal Marsden NHS Foundation Trust (RMH). The overarching aim of this study is to define the biological characteristics of early BC in older women in terms of tumour microenvironment (TME), molecular and genomic features. This analysis will include assessment of tumour infiltrating lymphocytes (TILs), and gene expression profiling with NanoString using the Breast Cancer 360 (BC360TM) assay measuring ribonucleic acid (RNA) expression signatures of genes involved in proliferation, endothelial, angiogenesis, cytotoxicity, stroma, inflammatory chemokines, and apoptosis. This analysis will examine various biological pathways, aiming to inform suitability for certain treatments including cyclin-dependent kinase inhibitors (CDKi), chemotherapy, immunotherapy, or targeted treatments such as phosphoinositide 3-kinases (PI3K) inhibitors, or deoxyribonucleic acid (DNA) damage response.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Breast Cancer Female

Currently open trials in the same condition.

NCT07505797 — ATUSA Ultrasound Diagnostic Imaging for Breast Lesions Evaluation (AUDIBLE) · recruiting
NCT07198724 — ERADICATE: A Phase Ib/II Study of Elacestrant Plus Trastuzumab Deruxtecan in Patients With CDK4/6 Inhibitor and Endocrin · Phase 1, PHASE2 · recruiting
NCT07331506 — Validation of the Oncoliq Test for the Early Detection of Breast Cancer. · recruiting
NCT07214883 — UCF MammoChat: Image Repository · recruiting
NCT07120100 — Transcranial Magnetic Stimulation for Chemotherapy-Induced Peripheral Neuropathy in Breast and Gynecologic Cancer Surviv · NA · recruiting

Other Royal Marsden NHS Foundation Trust trials

Trials by the same sponsor.

NCT07407686 — Improving Engagement From Underserved Communities With Prostate Cancer Genetics Services · not yet recruiting
NCT07243834 — Assessing a Digital Exercise Intervention for Health Outcomes and Engagement in Regular Exercise · NA · recruiting
NCT06605833 — CARDiac Toxicity Following ImmunOtherapy Treatment for Melanoma · enrolling by invitation
NCT07008742 — Feasibility Study of Tissue and Blood Collection in Oncogene-addicted and Neoadjuvantly Treated Non Small Cell Lung Canc · recruiting
NCT06560905 — Preoperative Planning With PSMA-PET in Melanoma Surgery Trial · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05734950 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Royal Marsden NHS Foundation Trust
Last refreshed: 21 February 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05734950.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing